CN102574839A - 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物 - Google Patents
有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物 Download PDFInfo
- Publication number
- CN102574839A CN102574839A CN2010800448681A CN201080044868A CN102574839A CN 102574839 A CN102574839 A CN 102574839A CN 2010800448681 A CN2010800448681 A CN 2010800448681A CN 201080044868 A CN201080044868 A CN 201080044868A CN 102574839 A CN102574839 A CN 102574839A
- Authority
- CN
- China
- Prior art keywords
- representes
- indoles
- pyrazoles
- cyanic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*(*)c1c2cc(C*C(ON)=O)cc1)=C2O Chemical compound CC(*(*)c1c2cc(C*C(ON)=O)cc1)=C2O 0.000 description 9
- QOVXTKAKZASBQB-UHFFFAOYSA-N CC(C)[n](ccc1c2)c1ccc2-[n]1nc(C(OC)=O)nc1 Chemical compound CC(C)[n](ccc1c2)c1ccc2-[n]1nc(C(OC)=O)nc1 QOVXTKAKZASBQB-UHFFFAOYSA-N 0.000 description 1
- HYGGAHFIAPCNFF-UHFFFAOYSA-N CC(C)[n]1c(ccc(-c2cc(C(O)=O)ccn2)c2)c2c([N+]([O-])=O)c1 Chemical compound CC(C)[n]1c(ccc(-c2cc(C(O)=O)ccn2)c2)c2c([N+]([O-])=O)c1 HYGGAHFIAPCNFF-UHFFFAOYSA-N 0.000 description 1
- OTMIYGLCTJPYGJ-UHFFFAOYSA-N CC(C)[n]1c(ccc(-c2ccc(C(O)=O)[s]2)c2)c2c(C#N)c1 Chemical compound CC(C)[n]1c(ccc(-c2ccc(C(O)=O)[s]2)c2)c2c(C#N)c1 OTMIYGLCTJPYGJ-UHFFFAOYSA-N 0.000 description 1
- MOWVUZMYQVHYOS-OCKHKDLRSA-N CC(C)[n]1c(ccc(-c2ccc(C(OC)=O)[s]2)c2)c2c(/C=N\O)c1 Chemical compound CC(C)[n]1c(ccc(-c2ccc(C(OC)=O)[s]2)c2)c2c(/C=N\O)c1 MOWVUZMYQVHYOS-OCKHKDLRSA-N 0.000 description 1
- HISFKRMAQGCDIT-UHFFFAOYSA-N CCC(C)[n]1c(ccc(-[n]2ncc(C(OCC)=O)c2)c2)c2c(C#N)c1 Chemical compound CCC(C)[n]1c(ccc(-[n]2ncc(C(OCC)=O)c2)c2)c2c(C#N)c1 HISFKRMAQGCDIT-UHFFFAOYSA-N 0.000 description 1
- LATLDNAGFPBRNJ-UHFFFAOYSA-N CCOC(c(nc1)c[n]1-c(cc1)cc2c1[nH]cc2)=O Chemical compound CCOC(c(nc1)c[n]1-c(cc1)cc2c1[nH]cc2)=O LATLDNAGFPBRNJ-UHFFFAOYSA-N 0.000 description 1
- FQRNJDHGEWZUAM-UHFFFAOYSA-N CCOC(c1c[n](-c(cc2)cc3c2[nH]cc3)nc1C)=O Chemical compound CCOC(c1c[n](-c(cc2)cc3c2[nH]cc3)nc1C)=O FQRNJDHGEWZUAM-UHFFFAOYSA-N 0.000 description 1
- COAPTMFDJVBLMU-UHFFFAOYSA-N CCOC(c1c[n](-c(cc2)cc3c2[nH]cc3C#N)nc1C)=O Chemical compound CCOC(c1c[n](-c(cc2)cc3c2[nH]cc3C#N)nc1C)=O COAPTMFDJVBLMU-UHFFFAOYSA-N 0.000 description 1
- RSTWFZFRXAUGKF-UHFFFAOYSA-N CCOC(c1c[n](-c(cc2)cc3c2[n](C(C)C)cc3[N+]([O-])=O)nc1)=O Chemical compound CCOC(c1c[n](-c(cc2)cc3c2[n](C(C)C)cc3[N+]([O-])=O)nc1)=O RSTWFZFRXAUGKF-UHFFFAOYSA-N 0.000 description 1
- GEYCBZREOUGLTQ-UHFFFAOYSA-N CCOC(c1c[n](-c(cc2)cc3c2[n](C2CC2)cc3C#N)nc1)=O Chemical compound CCOC(c1c[n](-c(cc2)cc3c2[n](C2CC2)cc3C#N)nc1)=O GEYCBZREOUGLTQ-UHFFFAOYSA-N 0.000 description 1
- PYMCWBWAULRJHF-UHFFFAOYSA-N COCC[n](cc(c1c2)C#N)c1ccc2-c1cc(C(O)=O)ccn1 Chemical compound COCC[n](cc(c1c2)C#N)c1ccc2-c1cc(C(O)=O)ccn1 PYMCWBWAULRJHF-UHFFFAOYSA-N 0.000 description 1
- RRZMCCWXSQIWQH-UHFFFAOYSA-N N#Cc(c1c2)c[n](C3COCC3)c1ccc2-c1cc(C(O)=O)ccn1 Chemical compound N#Cc(c1c2)c[n](C3COCC3)c1ccc2-c1cc(C(O)=O)ccn1 RRZMCCWXSQIWQH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
化合物(实施例编号) | IC50(nM) |
1 | 3.4 |
2 | 2.8 |
3 | 6 |
4 | 4.5 |
5 | 5 |
6 | 3.8 |
7 | 6.7 |
8 | 6.9 |
9 | 4.6 |
10 | 5.2 |
11 | 5.4 |
12 | 11.6 |
13 | 4.8 |
14 | 12 |
15 | 29200 |
16 | 21300 |
17 | 4.6 |
18 | 13 |
19 | 24 |
20 | 4.7 |
21 | 6.2 |
22 | 2.1 |
23 | 10 |
24 | 6.2 |
25 | 8.5 |
26 | 3940 |
27 | 11 |
28 | 24 |
29 | 5 |
30 | 17 |
31 | 40 |
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090095363 | 2009-10-07 | ||
KR10-2009-0095363 | 2009-10-07 | ||
PCT/KR2010/006760 WO2011043568A2 (en) | 2009-10-07 | 2010-10-04 | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102574839A true CN102574839A (zh) | 2012-07-11 |
CN102574839B CN102574839B (zh) | 2015-11-25 |
Family
ID=43857261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080044868.1A Active CN102574839B (zh) | 2009-10-07 | 2010-10-04 | 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8729273B2 (zh) |
EP (1) | EP2467378B1 (zh) |
JP (1) | JP5702392B2 (zh) |
KR (1) | KR101751325B1 (zh) |
CN (1) | CN102574839B (zh) |
AP (1) | AP3346A (zh) |
AR (1) | AR078504A1 (zh) |
AU (1) | AU2010304091B2 (zh) |
BR (1) | BR112012007828B8 (zh) |
CA (1) | CA2774133C (zh) |
CL (1) | CL2012000738A1 (zh) |
CO (1) | CO6430501A2 (zh) |
EA (1) | EA021025B1 (zh) |
EC (1) | ECSP12011793A (zh) |
ES (1) | ES2599829T3 (zh) |
HK (1) | HK1170224A1 (zh) |
IL (1) | IL218669A (zh) |
MA (1) | MA33880B1 (zh) |
MX (1) | MX2012003782A (zh) |
MY (1) | MY162813A (zh) |
PE (1) | PE20121088A1 (zh) |
SG (1) | SG179186A1 (zh) |
TR (1) | TR201203989T1 (zh) |
TW (1) | TWI423962B (zh) |
UA (1) | UA110197C2 (zh) |
WO (1) | WO2011043568A2 (zh) |
ZA (1) | ZA201202544B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774172A (zh) * | 2015-04-08 | 2015-07-15 | 河南师范大学 | 一种3-氰基吲哚类化合物的合成方法 |
CN106008488A (zh) * | 2016-05-20 | 2016-10-12 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
CN106478500A (zh) * | 2015-09-02 | 2017-03-08 | 广东东阳光药业有限公司 | 羧酸取代的(杂)芳环类衍生物及其制备方法和用途 |
CN110612286A (zh) * | 2017-02-28 | 2019-12-24 | 广东东阳光药业有限公司 | 氰基取代的稠合双环衍生物及其制备方法和用途 |
CN111072634A (zh) * | 2020-01-03 | 2020-04-28 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
CN111072647A (zh) * | 2019-12-11 | 2020-04-28 | 沈阳药科大学 | 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途 |
CN115160299A (zh) * | 2021-04-29 | 2022-10-11 | 江苏新元素医药科技有限公司 | 一类黄嘌呤氧化酶抑制剂 |
CN116836154A (zh) * | 2022-04-27 | 2023-10-03 | 江苏新元素医药科技有限公司 | 可用于痛风的化合物 |
WO2023208108A1 (zh) * | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | 可用于降尿酸的化合物 |
TWI844849B (zh) | 2021-05-07 | 2024-06-11 | 大陸商江蘇新元素醫藥科技有限公司 | 一類黃嘌呤氧化酶抑制劑 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Lg生命科學有限公司 | 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法 |
ES2629194T3 (es) * | 2011-08-30 | 2017-08-07 | Chdi Foundation, Inc. | Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de utilización del mismo |
RS57154B1 (sr) | 2013-03-29 | 2018-07-31 | Teijin Pharma Ltd | Derivat pirazola |
EP3169684B1 (en) | 2014-07-17 | 2019-06-26 | CHDI Foundation, Inc. | Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders |
BR112020022220A2 (pt) * | 2018-06-01 | 2021-02-02 | Autophagysciences Inc. | novo composto e composição farmacêutica compreendendo o mesmo |
PE20240139A1 (es) | 2020-11-04 | 2024-01-30 | Lg Chemical Ltd | Metodo para la preparacion de la composicion cristalina y farmaceutica acido 1-(3-ciano-1-isopropil-indol-5-yl)pirazol-4-carboxilico que lo comprende |
WO2022119270A1 (ko) * | 2020-12-01 | 2022-06-09 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제, 및 그의 제조방법 |
AU2021390901A1 (en) * | 2020-12-01 | 2023-06-08 | Lg Chem, Ltd. | Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid |
CN112920170B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | N-(吲哚-5-基)芳香杂环酰胺类化合物及其制备方法和用途 |
JP2024511899A (ja) | 2021-04-16 | 2024-03-15 | エルジー・ケム・リミテッド | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む経口用製剤 |
WO2022231261A1 (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
CN117255785A (zh) * | 2021-04-27 | 2023-12-19 | 株式会社Lg化学 | 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法 |
WO2022231262A1 (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제의 제조 방법 |
CN117412746A (zh) | 2021-06-15 | 2024-01-16 | 株式会社Lg化学 | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物 |
AR126164A1 (es) | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
BR112023026062A2 (pt) | 2021-07-02 | 2024-03-05 | Lg Chemical Ltd | Método para preparar um composto |
TWI822151B (zh) | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
CN116283946B (zh) * | 2023-03-27 | 2024-05-07 | 武汉工程大学 | 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
WO2008126898A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | (アザ)インドール誘導体及びその医薬用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645867B2 (en) | 1990-11-30 | 1994-01-27 | Teijin Pharma Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
US6635640B2 (en) * | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
DE60113543T2 (de) * | 2000-07-10 | 2006-07-13 | Bristol-Myers Squibb Co. | Zusammensetzung und antivirale wirkung von substituierten indol-oxo-aceto-piperidin-derivaten |
US20090286791A1 (en) * | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
WO2004014354A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
EP1911760A4 (en) | 2005-07-01 | 2010-06-02 | Nippon Chemiphar Co | xanthine oxidase inhibitor |
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
RU2515968C2 (ru) | 2007-04-11 | 2014-05-20 | Киссеи Фармасьютикал Ко., Лтд. | 5-членное гетероциклическое соединение и его применение для лекарственных целей |
WO2010044404A1 (ja) | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | 縮合複素環誘導体及びその医薬用途 |
JP5688660B2 (ja) | 2008-10-16 | 2015-03-25 | オートマチック バー コントロールス インコーポレイテッド | 食物製品のオンデマンド分配のための機器および方法およびターンテーブル |
JP5529876B2 (ja) * | 2008-10-17 | 2014-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 |
MX2012003539A (es) * | 2009-09-24 | 2012-04-30 | Hoffmann La Roche | Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). |
-
2010
- 2010-10-01 TW TW099133473A patent/TWI423962B/zh active
- 2010-10-04 SG SG2012018768A patent/SG179186A1/en unknown
- 2010-10-04 ES ES10822213.4T patent/ES2599829T3/es active Active
- 2010-10-04 KR KR1020100096578A patent/KR101751325B1/ko active IP Right Grant
- 2010-10-04 TR TR2012/03989T patent/TR201203989T1/xx unknown
- 2010-10-04 PE PE2012000438A patent/PE20121088A1/es active IP Right Grant
- 2010-10-04 BR BR112012007828A patent/BR112012007828B8/pt active IP Right Grant
- 2010-10-04 JP JP2012533074A patent/JP5702392B2/ja active Active
- 2010-10-04 WO PCT/KR2010/006760 patent/WO2011043568A2/en active Application Filing
- 2010-10-04 EA EA201270520A patent/EA021025B1/ru unknown
- 2010-10-04 MX MX2012003782A patent/MX2012003782A/es active IP Right Grant
- 2010-10-04 MA MA34731A patent/MA33880B1/fr unknown
- 2010-10-04 AU AU2010304091A patent/AU2010304091B2/en active Active
- 2010-10-04 US US13/498,253 patent/US8729273B2/en active Active
- 2010-10-04 AP AP2012006191A patent/AP3346A/xx active
- 2010-10-04 CA CA2774133A patent/CA2774133C/en active Active
- 2010-10-04 CN CN201080044868.1A patent/CN102574839B/zh active Active
- 2010-10-04 MY MYPI2012700104A patent/MY162813A/en unknown
- 2010-10-04 UA UAA201204342A patent/UA110197C2/ru unknown
- 2010-10-04 EP EP10822213.4A patent/EP2467378B1/en active Active
- 2010-10-05 AR ARP100103609A patent/AR078504A1/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218669A patent/IL218669A/en active IP Right Grant
- 2012-03-23 EC ECSP12011793 patent/ECSP12011793A/es unknown
- 2012-03-23 CO CO12049241A patent/CO6430501A2/es active IP Right Grant
- 2012-03-23 CL CL2012000738A patent/CL2012000738A1/es unknown
- 2012-04-10 ZA ZA2012/02544A patent/ZA201202544B/en unknown
- 2012-10-30 HK HK12110873.7A patent/HK1170224A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
WO2008126898A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | (アザ)インドール誘導体及びその医薬用途 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
CN104774172A (zh) * | 2015-04-08 | 2015-07-15 | 河南师范大学 | 一种3-氰基吲哚类化合物的合成方法 |
CN106478500A (zh) * | 2015-09-02 | 2017-03-08 | 广东东阳光药业有限公司 | 羧酸取代的(杂)芳环类衍生物及其制备方法和用途 |
CN106478500B (zh) * | 2015-09-02 | 2020-02-11 | 广东东阳光药业有限公司 | 羧酸取代的(杂)芳环类衍生物及其制备方法和用途 |
CN106008488A (zh) * | 2016-05-20 | 2016-10-12 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
CN110612286A (zh) * | 2017-02-28 | 2019-12-24 | 广东东阳光药业有限公司 | 氰基取代的稠合双环衍生物及其制备方法和用途 |
CN111072647A (zh) * | 2019-12-11 | 2020-04-28 | 沈阳药科大学 | 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途 |
CN111072634A (zh) * | 2020-01-03 | 2020-04-28 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
CN115160299A (zh) * | 2021-04-29 | 2022-10-11 | 江苏新元素医药科技有限公司 | 一类黄嘌呤氧化酶抑制剂 |
WO2022233264A1 (zh) | 2021-04-29 | 2022-11-10 | 江苏新元素医药科技有限公司 | 一类黄嘌呤氧化酶抑制剂 |
TWI844849B (zh) | 2021-05-07 | 2024-06-11 | 大陸商江蘇新元素醫藥科技有限公司 | 一類黃嘌呤氧化酶抑制劑 |
CN116836154A (zh) * | 2022-04-27 | 2023-10-03 | 江苏新元素医药科技有限公司 | 可用于痛风的化合物 |
WO2023208108A1 (zh) * | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | 可用于降尿酸的化合物 |
WO2023208103A1 (zh) * | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | 可用于痛风的化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102574839B (zh) | 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物 | |
CN106008340B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
CN114846005B (zh) | Shp2抑制剂及其应用 | |
KR102474640B1 (ko) | 카르복실산 화합물, 이의 제조방법, 및 이의 용도 | |
JP2020500207A (ja) | カルパインモジュレーター及びそれらの治療上の使用 | |
CN102224142B (zh) | 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物 | |
UA72611C2 (uk) | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази | |
CN108347942A (zh) | 乙型肝炎核心蛋白调节剂 | |
CN107108478B (zh) | Urat1抑制剂 | |
KR20100092909A (ko) | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
JP2010510201A (ja) | ステアリン酸CoA脱飽和酵素阻害剤としてのアセチレン誘導体 | |
CN101679262A (zh) | 吡啶酮化合物 | |
JP2006160733A (ja) | シアノフルオロピロリジン誘導体を有効成分として含有する医薬 | |
CN103459382B (zh) | 用于抑制pask的杂环化合物 | |
WO2020192570A1 (zh) | 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 | |
CN111434655A (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
CN101796033A (zh) | 作为cb1拮抗剂的取代的哌嗪 | |
CN114008028A (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
TW202244044A (zh) | 醫藥及醫藥品 | |
EP1633363B1 (en) | Pyridinyl acetonitriles | |
CN107428725A (zh) | 新杂环化合物,其制备方法以及包含其的药物组合物 | |
WO2004101514A1 (ja) | シアノフルオロピロリジン誘導体 | |
CN104884436B (zh) | 苯并氮杂衍生物及其医药用途 | |
CN101415701A (zh) | 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂 | |
CN103467481B (zh) | 二氢吡啶类化合物、其组合物、制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1170224 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1170224 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20171020 Address after: Seoul, South Kerean Patentee after: LG Chemical Ltd. Address before: Seoul, South Kerean Patentee before: LG Life Sciences Ltd |
|
TR01 | Transfer of patent right |